User profiles for Michael B Atkins
 | Michael AtkinsGeorgetown-Lombardi Comprehensive Cancer Ctr Verified email at georgetown.edu Cited by 109419 |
[HTML][HTML] Safety, activity, and immune correlates of anti–PD-1 antibody in cancer
…, RD Carvajal, JA Sosman, MB Atkins… - … England Journal of …, 2012 - Mass Medical Soc
Background Blockade of programmed death 1 (PD-1), an inhibitory receptor expressed by T
cells, can overcome immune resistance. We assessed the antitumor activity and safety of …
cells, can overcome immune resistance. We assessed the antitumor activity and safety of …
[HTML][HTML] Final version of 2009 AJCC melanoma staging and classification
…, S Soong, JF Thompson, MB Atkins… - Journal of clinical …, 2009 - ncbi.nlm.nih.gov
Purpose To revise the staging system for cutaneous melanoma on the basis of data from an
expanded American Joint Committee on Cancer (AJCC) Melanoma Staging Database. …
expanded American Joint Committee on Cancer (AJCC) Melanoma Staging Database. …
Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: American Society of Clinical Oncology Clinical Practice …
…, C Lacchetti, BJ Schneider, MB Atkins… - Journal of clinical …, 2018 - ascopubs.org
Purpose To increase awareness, outline strategies, and offer guidance on the recommended
management of immune-related adverse events in patients treated with immune …
management of immune-related adverse events in patients treated with immune …
[PDF][PDF] High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993
… Address reprint requests to Michael B. Atkins, MD, Division of Hematology and Oncology,
Beth Israel Deaconess Medical Center, 330 Brookline Ave, E/KS-158, Boston, MA 02215. 1999 …
Beth Israel Deaconess Medical Center, 330 Brookline Ave, E/KS-158, Boston, MA 02215. 1999 …
[HTML][HTML] Pembrolizumab plus axitinib versus sunitinib for advanced renal-cell carcinoma
Background The combination of pembrolizumab and axitinib showed antitumor activity in a
phase 1b trial involving patients with previously untreated advanced renal-cell carcinoma. …
phase 1b trial involving patients with previously untreated advanced renal-cell carcinoma. …
[PDF][PDF] Final version of the American Joint Committee on Cancer staging system for cutaneous melanoma
…, AC Buzaid, SJ Soong, MB Atkins… - Journal of Clinical …, 2001 - jfisher.pbworks.com
Purpose: To revise the staging system for cutaneous melanoma under the auspices of the
American Joint Committee on Cancer (AJCC). Materials and Methods: The prognostic factors …
American Joint Committee on Cancer (AJCC). Materials and Methods: The prognostic factors …
Melanoma staging: evidence‐based changes in the American Joint Committee on Cancer eighth edition cancer staging manual
…, RA Scolyer, MB Atkins… - CA: a cancer journal …, 2017 - Wiley Online Library
… Michael Atkins reports consulting fees from Bristol Myers Squibb, Merck, Novartis,
Genentech/Roche, Array, and Arduro. Antonio C. Buzaid reports contracted research and speakers …
Genentech/Roche, Array, and Arduro. Antonio C. Buzaid reports contracted research and speakers …
Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: ASCO guideline update
PURPOSE To increase awareness, outline strategies, and offer guidance on the recommended
management of immune-related adverse events (irAEs) in patients treated with immune …
management of immune-related adverse events (irAEs) in patients treated with immune …
[HTML][HTML] Adjuvant nivolumab versus ipilimumab in resected stage III or IV melanoma
Background Nivolumab and ipilimumab are immune checkpoint inhibitors that have been
approved for the treatment of advanced melanoma. In the United States, ipilimumab has also …
approved for the treatment of advanced melanoma. In the United States, ipilimumab has also …
Prognostic factors analysis of 17,600 melanoma patients: validation of the American Joint Committee on Cancer melanoma staging system
…, MI Ross, JM Kirkwood, MB Atkins… - Journal of clinical …, 2001 - ascopubs.org
PURPOSE: The American Joint Committee on Cancer (AJCC) recently proposed major
revisions of the tumor-node-metastases (TNM) categories and stage groupings for cutaneous …
revisions of the tumor-node-metastases (TNM) categories and stage groupings for cutaneous …